High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.

Checkpoint kinase 2 (CHK2) is a serine-threonine kinase with a role in DNA repair, cell cycle arrest or apoptosis in response to DNA damage. Both reduced and increased CHK2 expression has been described in different tumour types with impact on patient prognosis. To evaluate prevalence and significance of altered CHK2 expression in prostate cancer, a tissue microarray containing 17,747 tumours was analysed by immunohistochemistry. Nuclear CHK2 immunostaining was absent or weak in benign prostate epithelium but often more prominent in cancers. CHK2 immunostaining was considered weak in 38.8%, moderate in 33.6% and strong in 11.2% of prostate cancers. High CHK2 expression was strongly associated with TMPRSS2:ERG fusions (p<0.0001). Subgroup analysis of ERG positive and negative cancers revealed that high CHK2 staining was significantly linked to advanced tumour stage, high Gleason score, positive nodal status, positive surgical margin, high preoperative PSA (p<0.0001 each) and early prostate-specific antigen (PSA) recurrence (p=0.0001) in the subset of ERG negative cancers, while most of these associations were absent in ERG positive cancers. In ERG negative cancers, high CHK2 expression was an independent predictor of patient prognosis, even if parameters were included that were only available postoperatively. High CHK2 expression was also linked to presence of chromosomal deletions, high level of androgen receptor expression, positive p53 immunostaining, and high Ki-67 labelling index. These provide further in vivo evidence for previously described functional interactions. In summary, high CHK2 expression is linked to adverse tumour features and independently predicts early biochemical recurrence in ERG negative prostate cancer. CHK2 measurement, either alone or in combination, might be of clinical utility in this prostate cancer subgroup. Copyright © 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Citation

Till Eichenauer, Felix Federlein, Katharina Möller, Viktoria Chirico, Simon Kind, Maximilian Lennartz, Florian Lutz, Claudia Hube-Magg, Doris Höflmayer, Margit Fisch, Hartwig Huland, Hans Heinzer, Markus Graefen, Alexander Haese, Cornelia Schroeder, Patrick Lebok, Sarah Minner, Ronald Simon, Guido Sauter, Thorsten Schlomm, Waldemar Wilczak, Stefan Steurer, Andreas M Luebke. High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. Pathology. 2020 Jun;52(4):421-430

Mesh Tags

Substances

PMID: 32317175

search → result